Nanosynex

Company Overview

Snapshot

Founded in February 2017 by Diane Abensur and Michelle Heymann, Nanosynex operates with 1–10 employees. The company has raised $6.34 million across seven funding rounds, with a notable grant received in June 2025 from Synergy7 and Israel Innovation Authority.

Business overview

Nanosynex develops solutions to enhance testing quality and reduce healthcare costs by accelerating diagnostic processes. The company focuses on an innovative antimicrobial susceptibility test (AST) that utilizes a microfluidic disposable test cartridge platform and method to optimize bacterial growth. Its solution, comprising a disposable test platform, hardware, and analysis software, enables laboratories to perform same-day ASTs, facilitating targeted, personalized antibiotic prescriptions. Nanosynex operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare, Digital Medical Diagnostics, and Medical Decision Support, serving laboratories and healthcare providers globally.

Strategic signal

In January 2021, Nanosynex sought to introduce rapid COVID-19 tests to Israel, indicating a strategic pivot to address immediate public health crises beyond its core antimicrobial resistance focus. This move demonstrates the company's agility and potential to leverage its diagnostic technology for broader applications, signaling to investors its capacity for rapid adaptation and market responsiveness in critical healthcare areas.

Company Intelligence Q&A

What is Nanosynex's primary focus?

Nanosynex is primarily focused on developing and commercializing an innovative antimicrobial susceptibility test (AST) to improve testing quality and accelerate diagnostic processes.

When was Nanosynex founded and by whom?

Nanosynex was founded in February 2017 by co-founders Diane Abensur and Michelle Heymann.

What was a significant recent grant received by Nanosynex?

In June 2025, Nanosynex received a grant from Synergy7 and Israel Innovation Authority.

What is the total capital raised by Nanosynex?

Nanosynex has raised a total of $6.34 million across seven funding rounds.

What was Nanosynex's strategic move in early 2021?

In January 2021, Nanosynex sought to bring rapid COVID-19 tests to Israel, expanding its diagnostic efforts beyond antimicrobial resistance.